June 03, 2008
EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual MeetingJune 02, 2008
EntreMed’s ENMD-2076 Demonstrates Antitumor Activity in Multiple Myeloma ModelMay 13, 2008
EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare ConferenceMay 08, 2008
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed’s Selective Kinase InhibitorMay 02, 2008
EntreMed Reports First Quarter 2008 Financial ResultsApril 22, 2008
EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual MeetingApril 16, 2008
EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual MeetingApril 14, 2008
EntreMed’s Kinase Inhibitor, ENMD-2076, Presented During AACR Special SessionApril 11, 2008
EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual MeetingApril 09, 2008
EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical ProgramApril 07, 2008
Dr. Ronald E. Cape to Retire from EntreMed Board of DirectorsApril 04, 2008
EntreMed Receives Nasdaq Deficiency NoticeApril 02, 2008
EntreMed Commences Continuous Dosing Clinical Trial For MKC-1March 25, 2008
EntreMed to Present at BioCentury Future Leaders in the Biotech Industry ConferenceMarch 13, 2008
EntreMed Announces 2008 Corporate and Clinical Program PrioritiesMarch 06, 2008
EntreMed Reports Fourth Quarter and Year-End 2007 Financial ResultsFebruary 26, 2008
EntreMed to Present at the Jesup & Lamont Emerging Growth Stock ConferenceFebruary 21, 2008
EntreMed to Present at the 7th Annual North America Forum for Investing and Partnering in BiotechFebruary 05, 2008
EntreMed to Present at BIO CEO and Investor ConferenceJanuary 27, 2008
EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
